A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Cohort studyJournal of clinical medicine· Jul 2026

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Filippo Lixi, Mihaela-Madalina Timofte-Zorila, Mara-Ioana Tomi … Lacrinova Experience Working Group

Read paper

CorneaCohort studyTreatmentQ2IF 3.5

Dry eye symptoms improved substantially after 3 months of Ribohyal eye drops

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Filippo Lixi … Lacrinova Experience Working Group

Journal of clinical medicine · Jul 2026 · Q2 in General Medicine

Background

Dry Eye Disease (Dry Eye Disease) is a multifactorial condition with an impact on quality of life and an often suboptimal response to conventional lubricants.

Purpose

This study aimed at evaluating the real-world efficacy, tolerability, and patient adherence of a therapy with a novel ophthalmic solution containing Ribohyal, a riboflavin-hyaluronic acid complex, used in patients with Dry Eye Disease.

Methods

Were assessed before (T0) and after treatment (T1).

n = 5986 eyes

Results

patients reported markedly less dry eye discomfort after treatment

More results

BCVA and BUT significantly improved (from 0.08 ± 0.22 at T0 to 0.06 ± 0.19 logMAR at T1 and from 9.20 ± 4.49 to 11.85 ± 4.66 s at T1, respectively, both p < 0.001).

The prevalence of CFS decreased from 42.0% to 23.4% ( p < 0.001).

More results

Treatment acceptability was high, with mean scores of 8.88± 1.49 for tolerability, 8.55 ± 1.63 for adherence, and 8.62 ± 1.55 for perceived efficacy.

No relevant adverse events were reported.

“

Conclusion · 1 of 2

Lacrinova eye drops demonstrated significant improvements in both symptoms and clinical signs of Dry Eye Disease, with excellent tolerability and adherence.

Conclusion · 2 of 2

These findings support its use as an effective therapeutic option in routine clinical practice, although controlled studies are warranted to confirm the efficacy.

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Related papers